Potential impact of AUSFTA on Australia's blood supply

Glen A Kennedy, Judy Cummings and Simon T Durrant
Med J Aust 2007; 186 (8): . || doi: 10.5694/j.1326-5377.2007.tb00982.x
Published online: 16 April 2007

To the Editor: We read with great interest the article by Bambrick et al relating to the potential impact of the Australia–United States Free Trade Agreement (AUSFTA) on supply of blood products in Australia.1 Our recent experience with Octagam (Octapharma Australia, Sydney, NSW), an intravenous immunoglobulin (IVIg) product produced overseas, highlights some of the quality concerns raised in their article.

  • Glen A Kennedy
  • Judy Cummings
  • Simon T Durrant

  • Department of Haematology, Royal Brisbane and Women’s Hospital, Brisbane, QLD.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.